Q1 2024 · 13F-HR
Athyrium Capital Management, LPholdings as filed
Filed 2024-05-16 · accession 0001123292-24-000137
$72.8M
Reported value
3
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 682143AG7 | OMER 5.25 02/15/26 | Omeros Corp | $54.1M | 74.3% | 72,979,000 | Common | NONE |
| 74319F305 | — | Biora Therapeutics Inc. | $12.0M | 16.5% | 10,929,762 | Common | SOLE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $6.7M | 9.15% | 1,256,411 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.